Abstract
An epilogue, according to the dictionary, is “the final part that serves typically to round out or complete the design of a ... work” or provides “an afterword.” The editors thought an epilogue might be more appropriate than a summary of the papers of distinguished colleagues most of whom had, in any event, provided their own summaries or conclusions.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
G. L. Long, R. M. Belagaje and R. T. A. MacGilivray, Cloning and sequencing of liver cDNA coding for bovine protein C. Proc Natl Acad Sci U.S.A. 81:5653 (1984).
L. C. Pan and P. A. Price, The propeptide of rat bone gamma-carboxy-glutamic acid protein shares homology with other vitamin Independent protein precursors. Proc Nat Acad Sci U.S.A. 82:6109 (1985).
J. W. Suttie, J. A. Hoskins, J. Engelke, A. Hopfgartner, H. Ehrlich, N. U. Bang, R. M. Belagaje, B. Schoner, and G. L. Long, Vitamin K-dependent carboxylase: possible role of the “propeptide” as an intracellular recognition site (gamma-carboxyglutamic acid/ protein C), Proc Natl Acad Sci U.S.A. (1987) in press.
B. A. M. Soute, W. Muller-Esterl, M. A. G. de Boer-van den Berg, M. Ulrich and C. Vermeer, Discovery of a gamma-carboxyglutamic acid-containing protein in human spermatozoa. FEBS 190:137 (1985).
A. Faggiotto, R. Ross, L. Harker, Studies of hyperchloresterolemia in the non-human primate. I. Changes that lead to fatty streak formation. Arteriosclerosis 4:323 (1984).
A. Faggiotto, R. Ross, L. Harker, Studies of hyperchloresterolemia in the non-human primate. II. Changes that lead to fatty streak conversion to fibrous plaque. Arteriosclerosis 4:341 (1984).
T. W. Meade, W. R. S. North, R. Chakrabarti, Y. Stirling, A. P. Haines, S. G. Thompson and M. Brozovic, Haemostatic function and cardiovascular death: early results of a prospective study. Lancet I: 1050 (1980).
T. W. Meade, Y. Stirling, S. G. Thompson, M. V. Vickers, L. Woolf, A. B. Ajdukiewicz, G. Stewart, J. F. Davidson, I. D. Walker, A. S. Douglas, et al., An International and Interregional comparison of Haemostatic Variables in the study of Ischaemic Heart Disease. Report of a Working Group. Int J Epidemiology 15:331 (1986).
M. Zur, R. D. Radcliffe, J. Oberdick and Y. Nemerson, The dual role of factor VII in coagulation: initiation of coagulation by a zymogen. J Biol Chem 257:5623 (1982).
U. Seligsohn, C. K. Kasper, B. Osterud, S. I. Rapaport, Activated Factor VII: Presence in Factor IX concentrates and persistance in the circulation after infusion. Blood 53:828 (1979).
V. Hedner and W. Kisiel, Use of human factor VIIa in treatment of two haemophiliac A patients with high titer inhibitors. J Clin Invest 71:1836 (1983).
G. J. Miller, S. J. Walter, Y. Stirling, S. G. Thompson, M. P. Esnouf, T. W. Meade, Assay of Factor VII activity by two techniques: evidence for increased conversion of VII to alpha VIIa in hyperlipi-daemia, with possible implications for ischaemic heart disease. Brit J Haematology 59:249 (1985).
K. Dalaker, I. Hjermann, H. Prydz, A novel form of Factor VII in plasma for men at risk for cardiovascular disease. Brit J Haematology 61:315 (1985).
L. A. Salberg and J. P. Strong, Risk factors and atherosclerotic lesions: a review of autopsy studies. Arteriosclerosis 3:187 (1983).
T. Gordon, M. R. Garcia-Palmieri, A. Kagan, W. E. Kannel, and J. Schiffman, Differences in coronary heart disease in Framingham, Honolulu and Puerto Rico. J Chronic Dis 27:329 (1974).
J. Stamler and F. H. Epstein, Coronary heart disease: risk factors as guides to preventive action. Prev Med 1:27 (1972).
H. C. McGill, Jr., Risk factors in atherosclerosis. Adv Exp Med Biol 104:273 (1978).
The Framingham Study: an epidemiologic investigation of cardiovascular disease. Monograph sections 26–27. PHEW Publication. National Heart Institute (1970, 71).
J. Hermans, T. van den Besselaar, E. A. Loeliger, E. A. van der Veide, A collaborative calibration study of reference materials for thromboplastin. Thromb Haemost 50:712 (1983).
J. A. Koepke and D. A. Triplett, Standardization of the prothrombin time — finally. Arch Path Lab Med 109:800 (1985).
R. G. Berger and N. N. Hadler, Treatment of calcinosis universalis secondary to dermatomyositis or scleroderma with low dose warfarin. Presented at the annual meeting of the American Rheumatism Association, San Antonio, Texas. June 1–4, 1983.
M. M. Bern, A. Bothe, Jr., B. Bistrian, C. D. Champagne, M. S. Keane, G. L. Blackburn, Prophylaxis against central vein thrombosis with low-dose warfarin. Surgery 99:216 (1986).
M. Samama, M. H. Horellou, J. Soria, J. Conrad, G. Nicholas, Successful progressive anticoagulation in a severe protein C deficiency and previous skin necrosis at the initiation of oral anticoagulant treatment. Thromb Haemost 51:132 (1984).
P. Zauber and M. W. Stark, Successful warfarin anticoagulation despite protein C deficiency and a history of warfarin necrosis. Ann Int Med 104:659 (1986).
H. F. Dvorak, Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. New Eng J Med 315:1650 (1986).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Springer Science+Business Media New York
About this chapter
Cite this chapter
Wessler, S., Becker, C.G., Nemerson, Y. (1987). Epilogue. In: Wessler, S., Becker, C.G., Nemerson, Y. (eds) The New Dimensions of Warfarin Prophylaxis. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-5985-3_31
Download citation
DOI: https://doi.org/10.1007/978-1-4757-5985-3_31
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-5987-7
Online ISBN: 978-1-4757-5985-3
eBook Packages: Springer Book Archive